AI CDI & utilization review
35 – 41Waystar / Iodine Software by 6
| Dimension | Navina | Waystar / Iodine Software | Gap |
|---|---|---|---|
| EHR & deploymentDepth of EHR integration, concurrent versus retrospective review support, reviewer worklist prioritization, and the implementation burden on IT and HIM. | 7 | 10 | -3 |
| Capture accuracyHow reliably the tool finds genuine documentation gaps — diagnosis specificity, HCC recapture, severity and acuity capture — without flooding reviewers with false positives. | 8 | 9 | -1 |
| Revenue & denial impactDocumented effect on case mix index, DRG accuracy, denial rates and appeal outcomes, weighted toward externally reported results over vendor claims. | 8 | 9 | -1 |
| Access & transparencyPublished pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle. | 4 | 5 | -1 |
| Traceability & auditabilityWhether every suggested code or query anchors to a verbatim phrase in the record, and whether the audit trail would survive a payer or RAC review. | 8 | 8 | — |
Navina
- Best for
- Primary care and risk-bearing ambulatory groups that need longitudinal chart synthesis, HCC suspecting and point-of-care evidence linked back to labs and specialist notes.
- Limitation
- Purpose-built for outpatient value-based care and HCC workflows rather than inpatient DRG and acute utilization review.
- Price
- Enterprise and medical-group licensing, sales-led
Waystar / Iodine Software
- Best for
- Mid-sized and large hospitals that need AI cognitive emulation and chart prioritization to point a finite CDI team at the inpatient charts with the highest DRG and severity opportunity.
- Limitation
- Enterprise procurement only, with no published pricing and no self-serve evaluation path for small practices.
- Price
- Enterprise, sales-led; no published rate